Torrey Loper
Patients with structural heart disease can take very different routes before reaching the heart team. It can be difficult to reduce variability in care across the hospital system for this large patient population.
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,
Reducing variability in care for this patient population is critical to early identification and improving patient outcomes…
© 2025 egnite, Inc. All Rights Reserved. egnite, egnite Inc., CardioCare, the heart logo, and the spark logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.
Privacy Policy Intellectual Property Terms of Use Implementation Kit Careers